Oppenheimer initiated coverage on Cognition Therapeutics with a new price target

11/3/21 6:18:21 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Oppenheimer initiated coverage of Cognition Therapeutics with a rating of Outperform and set a new price target of $22.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CGTX

Date	Price Target	Rating	Analyst
12/19/2024	$1.00 → $1.50	Neutral → Buy	B. Riley Securities
7/30/2024		Overweight → Neutral	Cantor Fitzgerald
11/3/2021	$27.00	Buy	B. Riley Securities
11/3/2021	$22.00	Outperform	Oppenheimer